




RealRate

PHARMACEUTICAL 2012

DMK Pharmaceuticals Corp
Rank 173 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 5.0% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 198% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	1,534
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,113
Liabilities, Non-Current	0
Other Assets	200
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-739
Other Revenues	0
Property and Equipment	0
Research and Development	2,876
Selling, General and Administrative Expense	3,365

Output Variable	Value in 1000 USD
Assets	1,734
Liabilities	3,113
Expenses	6,241
Revenues	0
Stockholders Equity	-1,380
Net Income	-6,980
Comprehensive Net Income	-6,980
BaseVar	5,913
ECR before Limited Liability	-412%
Economic Capital Ratio	36%